Search results for:
Largest ALS patient-based stem cell, biodata resource opens for research
Answer ALS and Cedars-Sinai have made openly available their amyotrophic lateral sclerosis (ALS) patient-based stem cell and biodata repository to researchers worldwide. The largest of its kind, the repository contains biological and clinical data from nearly 1,000 ALS patients, as well as specialized nerve cells called induced pluripotent…
What I do when I’m feeling unmotivated in life with ALS
Can it be that we were cheering on athletes at the Olympics only a few months ago? Where did the summer go? Looking back, I realize I spent most of my summer and early fall months distracted by the hoopla of world and national events, and now I’m exhausted. I’m…
First-in-human trial of ALS therapy ASHA-624 expected in early 2025
A newly awarded grant from the ALS Association will support Asha Therapeutics‘ work to advance ASHA-624, a small molecule being developed for amyotrophic lateral sclerosis (ALS), into a first-in-human clinical trial that’s expected to begin early next year. The grant was through the Lawrence and Isabel Barnett…
Biopharmaceutical launches with goal to develop treatment for ALS
A new biopharmaceutical company has launched in the U.S. with more than $100 million in financing and a goal to develop a genomic medicine targeting the UNC13A protein as a novel treatment for people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Trace Neuroscience kicked off its…
GM604 for ALS
GM604 is an experimental therapy designed to slow disease progression in people with ALS. It was developed by Genervon to be given via injections into the bloodstream. While positive results were seen in a Phase 2a trial, its current development status is unknown.
The ALS Association
Established in 1985, The ALS Association (Amyotrophic Lateral Sclerosis Assn)Â is the only national nonprofit organization fighting ALS on every front.
Kadimastem, NLS merge to advance ALS therapy AstroRx, other drugs
Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS Pharmaceutics to combine efforts to advance both companies’ drug portfolios. The combined company will focus on moving AstroRx and a diabetes drug being developed by Kadimastem through clinical trials. A Phase…
Mitochondrial genome mutations linked to ALS in genetic study
Mutations in the mitochondrial genome — the set of DNA instructions found inside mitochondria, the powerhouses of cells — may be linked to amyotrophic lateral sclerosis (ALS), a study found. The findings open the door for new ways of diagnosing and treating the disease, researchers said. “We aren’t saying…
I AM ALS unveils new campaign aimed at supporting caregivers
This November, I AM ALS, a nonprofit dedicated to helping people — both patients and family members — affected by amyotrophic lateral sclerosis (ALS), is launching a campaign focused on supporting caregivers. The new initiative aims to raise awareness of the unique challenges faced by ALS caregivers. Throughout…